Dose-response assessment of tariquidar for inhibition of P-glycoprotein at the human blood-brain barrier using (R)-[11C]verapamil PET by Bauer, Martin et al.
MEETING ABSTRACT Open Access
Dose-response assessment of tariquidar for
inhibition of P-glycoprotein at the human
blood-brain barrier using (R)-[
11C]verapamil PET
Martin Bauer
1, Markus Zeitlinger
1, Peter Matzneller
1, Johann Stanek
1, Edith Lackner
1, Wolfgang Wadsak
2,
Markus Müller
1, Oliver Langer
1,3*
From 16th Scientific Symposium of the Austrian Pharmacological Society (APHAR)
Vienna, Austria. 25-27 November 2010
Background
Positron emission tomography (PET) with the radiola-
belled substrate of the multidrug efflux transporter P-
glycoprotein (P-gp) (R)-[
11C]verapamil (VPM) can be
used to assess P-gp function at the blood-brain barrier
(BBB). We have shown in rats that performing VPM
PET scans after half-maximum inhibition of P-gp with
the third-generation P-gp inhibitor tariquidar (TQD) is
more sensitive for detecting regional differences in cer-
ebral P-gp function than VPM baseline scans [1]. In
order to translate this concept to humans a detailed
understanding of the dose-response relationship of
TQD for inhibition of P-gp at the human BBB is
required.
Materials and methods
Healthy male subjects (n = 3 per dose group) underwent
VPM PET scans and arterial blood sampling at 1 h after
infusion of TQD at doses of 3, 4, 6 and 8 mg per kg
body weight. Brain uptake of radioactivity was quantified
as the ratio of the area under the time-activity curve
(AUC) in whole brain and in arterial plasma (AUCbrain/
AUCplasma). Radiometabolites of VPM in plasma were
assessed with a previously described solid-phase extrac-
tion protocol [2]. Data were pooled with data from a
previous pilot study in 5 healthy male subjects, who
underwent paired VPM PET scans before and after
administration of 2 mg/kg TQD [2].
Results
TQD was well tolerated in all but 1 subject, who
belonged to the 8 mg/kg dose group and experienced
mild hypotension and bradycardia as adverse events.
Administration of TQD at different doses exerted no
effect on the fraction of polar radiometabolites of VPM
in plasma. AUCbrain/AUCplasma increased with increasing
doses of TQD from 0.30 ± 0.06 for baseline scans to
0.74 ± 0.18 for the 4 mg/kg dose, but did not further
increase at doses >4 mg/kg.
Conclusions
Our data suggest that the half-maximum effect dose
(ED50) of TQD to enhance VPM-derived brain activity
uptake in humans is similar to the value previously
determined in rats using an identical study protocol
(3.0 ± 0.2 mg/kg) [1]. In humans complete inhibition of
P-gp at the BBB seemed to occur at TQD doses ≥4m g /
kg. The maximum increase in brain activity uptake was
several-fold lower in humans as compared to rats
(2.5 and 10-fold maximum increases relative to baseline
in rats and humans, respectively).
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